 Ranbaxy gets marketing nod for paediatric anti-retroviralsPublished on Fri, Dec 07, 2007 at 08:30 | Source : Business Line Updated at Fri, Dec 07, 2007 at 08:57 7170 Investors following GlaxoSmithKline. Share this News with them.
The products are designed to deliver two ARV drugs together in recommended strengths and simplify delivery of a more accurate treatment to children in resource poor settings, says Ranbaxy. Last year, the company had launched two Triple ARV combinations for children, Triviro-LNS kid and Triviro-LNS kid DS, taking its total paediatric ARVs to four. Ranbaxy Laboratories currently has 15 ARVs on the WHO pre-qualification list, of which three have US Food and Drug Administration's approval. Taken from Business Line
Trending NewsBusiness News
Tags: Ranbaxy, anti-HIV, Coviro-LS kid, ARV, WHO, GSK, Bristol Myers Squibb, Zerit, Malvinder Mohan Singh |
News Birla Corp Says Chanderia Mining Ops Stopped Following HC Order  The latest earning numbers FIRST on CNBC-TV18
Videos
Interviews
 May 28 2012, 20:00 | Source: CNBC-TV18  May 28 2012, 19:45 | Source: CNBC-TV18  Subscribe to Moneycontrol Newsletters |
||||||
